• T Klopfenstein, S Zayet, A Lohse, J-C Balblanc, J Badie, P-Y Royer, L Toko, C Mezher, N J Kadiane-Oussou, M Bossert, A-M Bozgan, A Charpentier, M-F Roux, R Contreras, I Mazurier, P Dussert, V Gendrin, T Conrozier, and HNF Hospital Tocilizumab multidisciplinary team.
• Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.
• Med Mal Infect. 2020 Aug 1; 50 (5): 397-400.

IntroductionNo therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.MethodWe conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.ResultsPatients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm3 vs 914/mm3, P=0.037 and higher CRP level: 158mg/L vs 105mg/L, P=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P=0.002).ConclusionDespite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.Copyright © 2020 Elsevier Masson SAS. All rights reserved.

48 keywords...

hide…